Alzheimer's Drug

• Decision on Eli Lilly’s Alzheimer’s drug delayed by U.S. FDA

  The U.S. Food and Drug Administration has delayed its decision on Eli Lilly's LLY.N experimental treatment for early Alzheimer's disease.

  Health

  Mar 8
  
• Drug to treat agitation in Alzheimer’s patients approved in Canada

  Health Canada has approved an oral drug to treat symptoms of agitation associated with dementia due to Alzheimer’s disease in patients.

  Canada

  Jan 25
  
• Advertisement
• 1st signs of Alzheimer’s may be detected in your eyes. This AI scan may help find it

  The relentless pursuit of detecting Alzheimer's has posed a grueling battle for families and the medical community, but a simple eye scan may help ease that burden.

  Health

  Jul 19, 2023
• Advertisement
• Alzheimer’s drug slows progression in patients. It may soon be approved in U.S.

  Another experimental Alzheimer’s drug can modestly slow patients’ inevitable worsening — by about four to seven months, researchers reported Monday.

  Health

  Jul 17, 2023
• Experimental Alzheimer’s drug slows disease, researchers say. Will it make a difference?

  An experimental Alzheimer's drug modestly slowed the brain disease's inevitable worsening, researchers reported Tuesday.

  Health

  Nov 30, 2022
• Alzheimer’s drug shows signs of slowing disease in early results of global study

  Eisai announced results late Tuesday from a global study of nearly 1,800 people with early-stage Alzheimer's.

  Health

  Sep 29, 2022
• U.S. drugmaker Lilly to submit ‘breakthrough’ Alzheimer’s drug to FDA

  The drugmaker said Thursday that it plans to submit its potential treatment donanemab to the Food and Drug Administration later this year.

  Health

  Jun 24, 2021
• U.S. FDA approves 1st new Alzheimer’s drug in nearly 20 years

  It's the only drug that U.S. regulators have said can likely treat the underlying disease, rather than manage symptoms like anxiety and insomnia.

  Health

  Jun 7, 2021
• Advertisement
• Company pushes Alzheimer’s drug amid conflicting results

  Aducanumab's developers stopped two studies earlier this year because it didn’t seem to be working, then did a stunning about-face in October and said new results suggest it was effective at a high dose.

  Science

  Dec 6, 2019